Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00717197 · ClinicalTrials.gov registry record · Phase 2
Study of Capecitabine to Treat Recurrent High Grade Gliomas
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00717197 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 30 participants.
The verdict
NCT00717197, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
Interventions
- DRUG Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00717197
The ClinicalTrials.gov registry entry for NCT00717197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capecitabine is the first listed.
NCT00717197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00717197 about?
NCT00717197 is a clinical study titled "Study of Capecitabine to Treat Recurrent High Grade Gliomas". The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
What is the current status of trial NCT00717197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00717197?
The interventions under investigation include: Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00717197?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.